Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication.
Keywords: immunotherapy; pembrolizumab; prophylaxis; tumor lysis syndrome.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.